Assessment of absolute lymphocyte count (ALC) as a predictor of progression-free survival (PFS) and overall response rate (ORR) in metastatic melanoma (MM) patients (pts) treated with high-dose interleukin-2 (HD IL-2).
Jeffrey Thomas Yorio
No relevant relationships to disclose
Patricia S Fox
No relevant relationships to disclose
Richard Wayne Joseph
No relevant relationships to disclose
Roland Bassett
No relevant relationships to disclose
Michael A. Davies
No relevant relationships to disclose